European Journal of Clinical Pharmacology

, Volume 14, Issue 3, pp 171–176 | Cite as

The effect of angiotensin II blockade by saralasin (1-Sar-8-Sla-angiotensin II) in normal man

  • H. Ibsen
  • A. M. Kappelgaard
  • M. Damkjær Nielsen
  • J. Giese


The effects of the angiotensin II analogue saralasin were investigated in 6 normal individuals. Blood pressure, plasma renin (PRC), plasma aldosterone (PAC) and plasma saralasin were measured before and during infusion of saralasin (0.54–5.4 nmol/kg/min) with the subjects supine. Plasma angiotensin II concentration (PA II) was measured before the infusion. In the sodium replete state, PA II averaged 11 pmol/1 (range 5 to 17). Saralasin infusion produced an increase in mean arterial pressure (MAP) and PAC, and a slight fall in PRC, which is consistent with an angiotensin II-like effect or a so-called agonistic effect. After sodium depletion, induced by hydrochlorothiazide 50–100 mg/day for 5 days, PA II was high −91 pmol/l on average (range 41 to 217). Angiotensin II blockade produced a fall in MAP in the supine position. The agonistic effect of saralasin on adrenal receptors during sodium depletion was less pronounced or absent. PRC increased sharply during the infusion. Infusion of saralasin at the rate of 5.4 nmol/kg/min produced a plasma saralasin concentration of about 220 nmol/l, i. e. in molar terms the plasma concentration of the analogue was 2000 to 10000 times higher than that of the endogenous octapeptide. The relationship between changes in MAP and basal PA II prior to infusion showed that saralasin exhibited a shift from agonistic to antagonistic properties on vascular receptors when pre-infusion PA II changed from approximately 20 to 40 pmol/l. A shift from agonistic to antagonistic effect on aldosterone secretion was not consistently seen. It is concluded that angiotensin II does not have a decisive role in the maintenance of normal blood pressure during normal sodium balance. However, after sodium depletion the renin-angiotensin system contributes to blood pressure control, even in the supine position. In addition to its antagonistic properties, saralasin possesses a weak agonistic effect on vascular, as well as on renal and adrenal receptors. This has to be taken into consideration when saralasin infusion is used to define “angiotensin II dependency” in patients with hypertension.

Key words

Angiotensin II angiotensin II antagonist aldosterone renin saralasin bloodpressure control 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Anderson, G. H., Streeten, H. P., Dalakos, T. G.: Pressor response to 1-Sar-8-Ala-angiotensin II (saralasin) in hypertensive subjects. Circ. Res.40, 243–250 (1977)Google Scholar
  2. Bing, J., Poulsen, K.: Time course of changes in plasma renin after blockade of the renin-system. Acta path. microbiol. scand. Sect. A,83, 454–466 (1975)Google Scholar
  3. Blair-West, J. R., Coghlan, J. P., Denton, D. A., Niall, H. D., Scoggins, B. A., Tregear, G. W.: Angiotensin II analogues and aldosterone secretion in sodium-deficient sheep. Clin. Sci. mol. Med.51, 325s-327s (1976)Google Scholar
  4. Brown, J. J., Brown, W. C. B., Fraser, R., Lever, R. F., Morton, J. J., Robertson, J. I. S., Rosei, E. A., Trust, P. M.: The effects of saralasin, an angiotensin II antagonist, on blood pressure and the renin-angiotensin-aldosterone system in normal and hypertensive subjects. Aust. N. Z. J. Med.6, 48–52 (1976)Google Scholar
  5. Gavras, H., Ribeiro, A. B., Gavras, I., Brunner, H. R.: Reciprocal relation between renin dependency and sodium dependency in essential hypertension. New Engl. J. Med.295, 1278–1283 (1976)Google Scholar
  6. Giese, J., Jørgensen, M., Nielsen, M. D., Lund, J. O., Munck, O.: Plasma renin concentration measured by use of radioimmunoassay for angiotensin I. Scand. J. clin. Lab. Invest.26, 355–367 (1970)Google Scholar
  7. Hollenberg, N. K., Chenitz, W. R., Adams, D. F., Williams, G. H.: Reciprocal influence of salt intake on adrenal glomerulosa and renal vascular responses to angiotensin II in normal man. J. clin. Invest.54, 34–42 (1974)Google Scholar
  8. Hollenberg, N. K., Williams, G. H., Burger, B., Ishikawa, I., Adams, D. F.: Blockade and stimulation of renal, adrenal, and vascular angiotensin II receptors with 1-sar, 8-ala angiotensin II in normal man. J. clin. Invest.57, 39–46 (1976)Google Scholar
  9. Kappelgaard, A. M., Nielsen, M. D., Giese, J.: Measurement of angiotensin II in human plasma: Technical modifications and practical experience. Clin. Chim. Acta67, 299–306 (1976)Google Scholar
  10. Kappelgaard, A. M., Ibsen, H., Nielsen, M. D., Giese, J.: Radioimmunoassay for saralasin by means of anti-angiotensin II sera. Clin. Chim. Acta83, 25–31 (1978)Google Scholar
  11. Keenan, R. E., Horne, M. L., Conklin, V. M.: Angiotensin II blockade. New Engl. J. Med.297, 52–54 (1977)Google Scholar
  12. MacGregor, G. A., Dawes, P. M.: Agonist and antagonist effects of sar1-ala8-angiotensin II in salt-loaded and salt-depleted normal man. Br. J. clin. Pharmacol.3, 483–487 (1976)Google Scholar
  13. Marks, L. S., Maxwell, M. H., Kaufman, J. J.: Renin, sodium, and vasodepressor response to saralasin in renovascular and essential hypertension. Ann. int. Med.87, 176–182 (1977)Google Scholar
  14. Mason, P. A., Fraser, R., Morton, J. J., Semple, P. F., Wilson, A.: The effect of sodium deprivation and of angiotensin II infusion on the peripheral plasma concentrations of 18-hydroxycorticosterone, aldosterone and other corticosteroids in man. J. Steroid Biochem.8, 799–804 (1977)Google Scholar
  15. Mayes, D., Furuyama, S., Kem, D. C., Nugent, C. A.: A radioimmunoassay for plasma aldosterone. J. clin. Endocrinol.30, 682–685 (1970)Google Scholar
  16. McGrath, B. P., Ledingham, J. G. G., Benedict, C. R.: Plasma catecholamines and the pressor response to sar1-ala8-angiotensin II in man. Clin. Sci. mol. Med.53, 341–346 (1977)Google Scholar
  17. Noth, R. H., Tan, S. Y., Mulrow, P. J.: Effects of angiotensin II blockade by saralasin in normal man. J. clin. Endocrinol. Metab.45, 10–15 (1977)Google Scholar
  18. Pettinger, W. A., Keeton, K., Tanaka, K.: Radioimmunoassay and pharmacokinetics of saralasin in the rat and hypertensive patients. Clin. Pharmacol. Ther.17, 146–158 (1975)Google Scholar
  19. Posternak, L., Brunner, H. R., Gavras, H., Brunner, D. B.: Angiotensin II blockade in normal man: Interaction of renin and sodium in maintaining blood pressure. Kidney Internat.11, 197–203 (1977)Google Scholar
  20. Sancho, J., Re, R., Burton, J., Barger, A. C., Haber, E.: The role of the renin-angiotensin-aldosterone system in cardio-vascular homeostasis in normal human subjects. Circulation53, 400–405 (1976)Google Scholar
  21. Stephens, G. A., Davis, J. O., Freeman, R. H., Watkins, B. E., Khosla, M. C.: The effects of angiotensin II blockade in conscious sodium-depleted dogs. Endocrinology101, 378–388 (1977)Google Scholar

Copyright information

© Springer-Verlag 1978

Authors and Affiliations

  • H. Ibsen
    • 1
  • A. M. Kappelgaard
    • 1
  • M. Damkjær Nielsen
    • 1
  • J. Giese
    • 1
  1. 1.Department of Clinical PhysiologyGlostrup HospitalGlostrupDenmark

Personalised recommendations